Abstract
CD23 is a low-affinity receptor for immunoglobulin E (IgE) expressed by a variety of haematopoietic cells. Proteolytic cleavage of the transmembrane receptor generates soluble forms, which can be detected in biological fluids. CD23 regulates many functional aspects of immune cells, both in its cell-associated and soluble forms. In view of the increased levels of CD23 in rheumatoid arthritis, we have studied the effect of neutralizing CD23 in type II collagen-induced arthritis in mice, a model for human rheumatoid arthritis. Successful disease modulation is achieved by treatment of arthritic DBA/1 mice with either polyclonal or monoclonal antibodies to mouse CD23. Treated mice show a dose-related amelioration of arthritis with significantly reduced clinical scores and number of affected paws. This improvement in clinical severity is confirmed by histological examination of the arthritic paws. A marked decrease in cellular infiltration of the synovial sublining layer and limited destruction of cartilage and bone is evident in animals treated with therapeutic doses of anti-CD23 antibody. These findings demonstrate the involvement of CD23 in a mouse model of human rheumatoid arthritis.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
References
Conrad, D.H. Fc epsilon RII/CD23: The low Affinity receptor for IgE. Annu. Rev. Immun. 8, 623–645 (1990).
Delespesse, G. et al. Expression, structure, and function of the CD23 antigen. Adv. Immun. 49, 149–191 (1991).
Bonnefoy, J.Y. et al. Receptors for IgE. Curr. Opin. Immun. 5, 944–949 (1993).
Lecoanet-Henchoz, S. et al. CD23 regulates monocyte activation through a novel interaction with the adhesion molecules CD lib/CD 18 and CDllc/CD18. Immunity (in the press).
Herbelin, A., Elhadad, S., Ouaaz, F., de Groote, D. & Descamps-Latscha, B. Soluble CD23 potentiates interleukin-1-induced secretion of interleukin-6 and interleukin-1 receptor antagonist by human monocytes. Eur. J. Immun. 24, 1869–1873 (1994).
Armant, M., Ishihara, H., Rubio, M., Delespesse, G. & Sarfati, M. Regulation of cytokine production by soluble CD23: Costimulation of interferon gamma secretion and triggering of tumor necrosis factor a release. J. exp. Med. 180, 1005–1011 (1994).
Bansal, A.S., Oilier, W., Marsh, M.N., Pumphrey, R.S. & Wilson, P.B. Variations in serum sCD23 in conditions with either enhanced humoral or cell-mediated immunity. Immunology 79, 285–289 (1993).
Hellen, E.A., Rowlands, D.C., Hansel, T.T., Kitas, G.D. & Crocker, J. Immunohistochemical demonstration of CD23 expression on lymphocytes in rheumatoid synovitis. J. clin. Pathol. 44, 293–296 (1991).
Chomarat, P., Briolay, J., Banchereau, J. & Miossec, P. Increased production of soluble CD23 in rheumatoid arthritis, and its regulation by interleukin-4. Arthritis Rheum. 36, 234–242 (1993).
Bansal, A. et al. Soluble CD23 levels are elevated in the serum of patients with primary Sjögren's syndrome and systemic lupus erythematosus. Clin. exp. Immun. 89, 452–455 (1992).
Rezonzew, R. & Newkirk, M.M. Impaired release of sCD23 by activated B-cells from RA patients. Clin. Immunol. Immunopathol. 71, 156–163 (1994).
Bansal, A.S. et al. Increased levels of sCD23 in rheumatoid arthritis are related to disease status. Clin. exp. Rheumatol. 12, 281–285 (1994).
Brennan, F.M., Chantry, D., Jackson, A., Maini, R. & Feldmann, M. Inhibitory effect of TNF alpha antibodies on synovial cell interleukin-1 production in rheumatoid arthritis. Lancet 2, 244–247 (1989).
Feldmann, M. et al. Cytokine assays: Role in evaluation of the pathogenesis of autoimmunity. Immunol. Rev. 119, 105–123 (1991).
Brennan, F.M., Maini, R.N. & Feldmann, M. TNF alpha—A pivotal role in rheumatoid arthritis? Br. J. Rheumatol. 31, 293–298 (1992).
Chu, C.Q., Field, M., Feldmann, M. & Maini, R.N. Localization of tumor necrosis factor alpha in synovial tissues and at the cartilage-pannus junction in patients with rheumatoid arthritis. Arthritis Rheum. 34, 1125–1132 (1991).
Elliott, M.J. et al. Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumour necrosis factor-alpha. Arthritis Rheum. 36, 1681–1690 (1993).
Williams, R.O., Feldmann, M. & Maini, R.N. Anti-tumor necrosis factor ameliorates joint disease in murine collagen-induced arthritis. Proc. natn. Acad. Sci. U.S.A. 89, 9784–9788 (1992).
Piguet, P.F. et al. Evolution of collagen arthritis in mice is arrested by treatment with anti-tumour necrosis factor (TNF) antibody or a recombinant soluble TNF receptor. Immunology 77, 510–514 (1992).
Wooley, P.H., Dutcher, J., Widmer, M.B. & Gillis, S. Influence of a recombinant human soluble tumour necrosis factor receptor Fc fusion protein on type II collagen-induced arthritis in mice. J. Immun. 151, 6602–6607 (1993).
Wooley, P.H. et al. The effect of an interleukin-1 receptor antagonist protein on type II collagen-induced arthritis and antigen-induced arthritis in mice. Arthritis Rheum. 36, 1305–1314 (1993).
Van den Berg, W.B., Joosten, L.A.B., Helsen, M. & van de Loo, F.A.J. Amelioration of established murine collagen-induced arthritis with anti-IL-1 treatment. Clin. exp. Immun. 95, 237–243 (1994).
Field, M., Chu, C., Feldmann, M. & Maini, R.N. Interleukin-6 localisation in the synovial membrane in rheumatoid arthritis. Rheumatol. Int. 11, 45–50 (1991).
Wendling, D., Racadot, E. & Wijdenes, J. Treatment of severe rheumatoid arthritis by anti-interleukin 6 monoclonal antibody. J. Rheumatol. 20, 259–262 (1993).
Stuart, J.M., Townes, A.S. & Kang, A.H. Collagen autoimmune arthritis. Annu. Rev. Immun. 2, 199–218 (1984).
Trentham, D.E. Collagen arthritis as a relevant model for rheumatoid arthritis. Arthritis Rheum. 25, 911–916 (1982).
Flores-Romo, L. et al. Inhibition of an in vivo antigen-specific IgE response by antibodies to CD23. Science 261, 1038–1041 (1993).
Wooley, P.H. et al. Type II collagen-induced arthritis in mice. HI. Suppression of arthritis by using monoclonal and polyclonal anti-la antisera. J. Immun. 134, 2366–2374 (1985).
Rao, M., Lee, W.T. & Conrad, D.H. Characterization of a monoclonal antibody directed against the murine B lymphocyte receptor for IgE. J. Immun. 138, 1845–1851 (1987).
Plater-Zyberk, C., Taylor, P.C., Blaylock, M.G. & Maini, R.N. Anti-CD5 therapy decreases severity of established disease in collagen type Il-induced arthritis in DBA/1 mice. Clin. exp. Immun. 98, 442–447 (1994).
Aubry, J.P., Pochon, S., Graber, P., Jansen, K.U. & Bonnefoy, J.Y. CD21 is a lig-and for CD23 and regulates IgE production. Nature 358, 505–507 (1992).
Marcelletti, J.F., Ohara, J. & Katz, D.H. Collagen-induced arthritis in mice. Relationship of collagen-specific and total IgE synthesis to disease. J. Immun. 147, 4185–4191 (1991).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Plater-Zyberk, C., Bonnefoy, JY. Marked amelioration of established collagen-induced arthritis by treatment with antibodies to CD23 in vivo. Nat Med 1, 781–785 (1995). https://doi.org/10.1038/nm0895-781
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1038/nm0895-781
This article is cited by
-
Activation of the P2X7 receptor induces the rapid shedding of CD23 from human and murine B cells
Immunology & Cell Biology (2015)
-
IgE and mast cells in allergic disease
Nature Medicine (2012)
-
IgE in allergy and asthma today
Nature Reviews Immunology (2008)
-
ADAM10 is a principal 'sheddase' of the low-affinity immunoglobulin E receptor CD23
Nature Immunology (2006)
-
Antigen presentation in allergic sensitization
Immunology & Cell Biology (1996)